'We must be doing something right': Carlisle chippy 'proud' to be in final
WE'RE highlighting the shortlisted chip shops in our competition in the News & Star. Each of the establishments will be featured over ten issues.
Morton Fryer has been nominated by News & Star readers as one of ten finalists in its 'Best Chippy 2025' award.
The family-run shop has been a staple in Stonegarth for 15 years and it is owned by Serkan Topuz who has been in the chippy industry for over two decades.
This is the shop's fifth year running making the top ten list and Serkan said he feels proud to be nominated once again.
He said: 'It's great to be nominated for the fifth year – we must be doing something right! I feel so proud.
'I think there's three reasons for our nomination. We pride ourselves on the quality of our food, our good service, and our hygiene, and we are a very clean shop.'
Being in the industry for over half of his life, Serkan told the News & Star his favourite thing about it is the people.
Their famous fish and chips. (Image: Supplied)READ MORE: Village shop 'over the moon' to be named finalist in 'Best Chippy' competition
'My favourite part about working in the fish and chips industry is definitely serving the public.
'Seeing our regulars every day is a great feeling, for us it's not like serving customers, it's like serving someone we know. We take good care of them. I think we're in a good location in the local area too, so we get involved in the community.'
Fish and chips are the top seller at the Morton Fryer, with the busiest months running from March through to New Year.
Although rising prices of ingredients are a growing challenge, Serkan remains committed to maintaining the team's high quality takeaway food.
He added: 'Thank you to all our customers for the nomination, our regulars and new ones. I've been working in Carlisle for 15 years now and I'm proud to serve you all.'
News & Star readers will now be able to vote for their favourite finalist by picking up a copy of the daily newspaper between Monday, June 2, and Sunday, June 14.
Morton Fryer is open Tuesday to Saturday, 11am until 1:30pm and then 3pm until 9pm.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Shams Charania Drops Major Kevin Durant Trade Update on Wednesday
Shams Charania Drops Major Kevin Durant Trade Update on Wednesday originally appeared on Athlon Sports. According to Shams Charania of ESPN, the Phoenix Suns are hiring Cleveland Cavaliers assistant Jordan Ott as their new head coach. Advertisement The Suns fired Mike Budenholzer after one season. Budenholzer replaced Frank Vogel, who was also fired after one season. Phoenix missed the playoffs and play-in tournament this year despite having Kevin Durant, Devin Booker and Bradley Beal. Charania is reporting that Booker was involved in the Suns' coaching search process during the final stages and stamped Ott as his top choice. Durant, though, wasn't involved. That's because the Suns are expected to work together with the superstar and his business partner, Boardroom CEO Rich Kleiman, on a trade. "The Suns will work with All-Star forward Kevin Durant and his business partner, Boardroom CEO Rich Kleiman, on his next landing spot," Charania wrote. "He is expected to have a robust market of approximately four to six seriously interested teams this offseason, sources said." Phoenix Suns star Kevin Chenoy-Imagn Images A future Hall of Famer, Durant has one year remaining on his contract. The small forward will make $54.7 million next season. Advertisement Durant turns 37 in September. He averaged 26.6 points, 6.0 rebounds and 4.2 assists for the Suns this season while shooting 52.7% from the field, 43.0% from beyond the arc and 83.9% from the free-throw line. Durant has career averages of 27.2 points, 7.0 rebounds and 4.4 assists with the Oklahoma City Thunder, Golden State Warriors, Brooklyn Nets and Suns. KD won two championships and two Finals MVPs with the Warriors but hasn't gotten back to the NBA Finals since leaving Golden State for Brooklyn in 2019. The Suns acquired Durant from the Nets in 2023. They have won only one postseason series since then. Related: Suns Could Trade Kevin Durant to Texas Team 'Right Before' 2025 NBA Draft This story was originally reported by Athlon Sports on Jun 4, 2025, where it first appeared.
Yahoo
17 hours ago
- Yahoo
Brookfield Corporation Announces Results of Annual and Special Meeting of Shareholders
BROOKFIELD, NEWS, June 06, 2025 (GLOBE NEWSWIRE) -- Brookfield Corporation ('Brookfield') (NYSE: BN, TSX: BN) today announced that all eight nominees proposed for election to the board of directors by holders of Class A Limited Voting Shares ('Class A Shares') and all eight nominees proposed for election to the board of directors by the holder of Class B Limited Voting Shares ('Class B Shares') were elected at the company's Annual and Special Meeting of Shareholders held on June 6, 2025 in a virtual meeting format. Detailed results of the vote for the election of directors are set out below. Management received the following proxies from holders of Class A Shares in regard to the election of the eight directors nominated by this shareholder class: Director Nominee Votes For % Votes Withheld % M. Elyse Allan 1,115,730,515 99.34 7,447,479 0.66 Janice Fukakusa 1,105,417,333 98.42 17,760,661 1.58 Maureen Kempston Darkes 1,098,031,177 97.76 25,146,817 2.24 Frank J. McKenna 1,039,694,592 92.57 83,483,402 7.43 Hutham S. Olayan 1,107,930,924 98.64 15,247,070 1.36 Satish C. Rai 1,120,574,949 99.77 2,603,045 0.23 Diana L. Taylor 1,066,550,620 94.96 56,627,374 5.04 Justin B. Beber 832,746,877 74.14 290,431,117 25.86Management received a proxy from the holder of Class B Shares to vote all 85,120 Class B Shares for each of the eight directors nominated by this shareholder class: Director Nominee Votes For % Howard S. Marks 100.0 Rafael Miranda 100.0 Lord O'Donnell 100.0 Jeffrey M. Blidner 100.0 Jack L. Cockwell 100.0 Bruce Flatt 100.0 Brian D. Lawson 100.0 Samuel J.B. Pollock 100.0A summary of all votes cast by holders of the Class A and Class B Shares represented at the company's Annual and Special Meeting of Shareholders is available on SEDAR+ at About Brookfield Corporation Brookfield Corporation is a leading global investment firm focused on building long-term wealth for institutions and individuals around the world. We have three core businesses: Alternative Asset Management, Wealth Solutions, and our Operating Businesses which are in renewable power, infrastructure, business and industrial services, and real estate. We have a track record of delivering 15%+ annualized returns to shareholders for over 30 years, supported by our unrivaled investment and operational experience. Our conservatively managed balance sheet, extensive operational experience, and global sourcing networks allow us to consistently access unique opportunities. At the center of our success is the Brookfield Ecosystem, which is based on the fundamental principle that each group within Brookfield benefits from being part of the broader organization. Brookfield Corporation is publicly traded in New York and Toronto (NYSE: BN, TSX: BN). For more information, please visit our website at or contact: Media Investor Relations Kerrie McHugh Katie Battaglia Tel: (212) 618-3469 Tel: (416) 359-8544 Email: Email: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
a day ago
- Business Wire
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress
BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, taking place June 13-16, 2025 in Glasgow, United Kingdom. Dr. William Yang, M.D., FRCPC, FAAAAI, Managing Director and Chair, Ottawa Allergy Research Corporation, will present combined initial safety and efficacy data from the Phase 1b/2 and long-term open label trials of navenibart in a late-breaking poster presentation of poster number D1.390 titled, 'Long-term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema (HAE): Initial Combined Results from ALPHA-STAR and ALPHA-SOLAR.' The presentation will take place on Friday, June 13 in a poster session beginning at 12:00pm BST. Nikolaos Biris, Ph.D., Senior Director of Structural and Functional Biology at Astria Therapeutics, will present information on the differentiation of STAR-0310 in a presentation of poster number D1.343 titled, 'Unveiling the Underlying Mechanism of Differentiation for STAR-0310, an Anti-OX40 Antibody for Atopic Dermatitis.' The presentation will take place on Friday, June 13 in a poster session beginning at 12:00pm BST. Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the University of Texas Health Science Center at Dallas, will present data from the Phase 1b/2 trial of navenibart in a presentation of poster number D3.391 titled, 'Results from the ALPHA-STAR Trial, a Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Navenibart in Participants with Hereditary Angioedema (HAE).' The presentation will take place on Sunday, June 15 in a poster session beginning at 12:45pm BST. Dr. Emel Aygören-Pürsün, M.D., Goethe University, Frankfurt, Germany, will present information on the global Phase 3 trial of navenibart in a presentation of poster number D3.390 titled, 'ALPHA-ORBIT: a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants with Hereditary Angioedema (HAE).' The presentation will take place on Sunday, June 15 in a poster session beginning at 12:45pm BST. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn.
